{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:23:52Z","timestamp":1761845032286,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Hispania","award":["The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Madrid, Spain"],"award-info":[{"award-number":["The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Madrid, Spain"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5753-7","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T16:02:52Z","timestamp":1559577772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8140","authenticated-orcid":false,"given":"A.","family":"Carrato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Benavides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Massut\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ferreiro-Monteagudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garc\u00eda Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reboredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Vi\u00e9itez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Layos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dotor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dur\u00e1n-Ogalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodriguez-Garrote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"issue":"2","key":"5753_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5753_CR2","first-page":"56","volume":"14","author":"AEM van der Pool","year":"2012","unstructured":"van der Pool AEM, Damhuis RA, Ijzermans JNM, de Wilt JHW, Eggermont AMM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2012;14(1):56\u201361.","journal-title":"Colorectal Dis Off J Assoc Coloproctology G B Irel"},{"issue":"5","key":"5753_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LGM van der Geest","year":"2015","unstructured":"van der Geest LGM, J\u2019t L-B, Koopman M, Verhoef C, MAG E, de JHW W. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457\u201365.","journal-title":"Clin Exp Metastasis"},{"issue":"5","key":"5753_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10522-010-9287-2","volume":"11","author":"T Fulop","year":"2010","unstructured":"Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, et al. Aging, frailty and age-related diseases. Biogerontology. 2010;11(5):547\u201363.","journal-title":"Biogerontology."},{"issue":"5","key":"5753_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1159\/000211949","volume":"55","author":"P-O Lang","year":"2009","unstructured":"Lang P-O, Michel J-P, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009;55(5):539\u201349.","journal-title":"Gerontology."},{"key":"5753_CR6","unstructured":"Huisingh-Scheetz M, Walston J. How should older adults with cancer be evaluated for frailty? J Geriatr Oncol. 2016; [Internet] [cited 2016 Aug 20]. Available from: \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406816300601\n                    \n                  ."},{"issue":"9779","key":"5753_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet Lond Engl. 2011;377(9779):1749\u201359.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"5753_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/annonc\/mdv491","volume":"27","author":"T Aparicio","year":"2016","unstructured":"Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2016;27(1):121\u20137.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"9","key":"5753_CR9","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross K, Frost A, Steinbild S, Hedbom S, B\u00fcchert M, Fasol U, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(9):2658\u201367.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"5753_CR10","first-page":"105","volume":"49","author":"SL Davis","year":"2013","unstructured":"Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today Barc Spain 1998. 2013;49(2):105\u201315.","journal-title":"Drugs Today Barc Spain 1998"},{"issue":"9863","key":"5753_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2013;381(9863):303\u201312.","journal-title":"Lancet Lond Engl."},{"issue":"11","key":"5753_CR12","first-page":"1371","volume":"51","author":"J Sastre","year":"2015","unstructured":"Sastre J, Massuti B, Pulido G, Guill\u00e9n-Ponce C, Benavides M, Manzano JL, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer Oxf Engl 1990. 2015;51(11):1371\u201380.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"5753_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.critrevonc.2009.11.005","volume":"77","author":"J Sastre","year":"2011","unstructured":"Sastre J, Aranda E, Gr\u00e1valos C, Massut\u00ed B, Varella-Garcia M, Rivera F, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011;77(1):78\u201384.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"5753_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1634\/theoncologist.2011-0406","volume":"17","author":"J Sastre","year":"2012","unstructured":"Sastre J, Gr\u00e1valos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study. Oncologist. 2012;17(3):339\u201345.","journal-title":"Oncologist"},{"issue":"11","key":"5753_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077\u201385.","journal-title":"Lancet Oncol."},{"issue":"8","key":"5753_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Lenz H-J, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937\u201348.","journal-title":"Lancet Oncol."},{"issue":"5","key":"5753_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrclinonc.2009.38","volume":"6","author":"ME Gutierrez","year":"2009","unstructured":"Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol. 2009;6(5):259\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"30","key":"5753_CR18","doi-asserted-by":"publisher","first-page":"28716","DOI":"10.18632\/oncotarget.4747","volume":"6","author":"G Aprile","year":"2015","unstructured":"Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, et al. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget. 2015;6(30):28716\u201330.","journal-title":"Oncotarget."},{"issue":"12","key":"5753_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1634\/theoncologist.2014-0237","volume":"19","author":"N Ommundsen","year":"2014","unstructured":"Ommundsen N, Wyller TB, Nesbakken A, Jordh\u00f8y MS, Bakka A, Skovlund E, et al. Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 2014;19(12):1268\u201375.","journal-title":"Oncologist"},{"key":"5753_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","volume":"16","author":"A Adenis","year":"2016","unstructured":"Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.","journal-title":"BMC Cancer"},{"issue":"6","key":"5753_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619\u201329.","journal-title":"Lancet Oncol"},{"issue":"8","key":"5753_CR22","first-page":"942","volume":"51","author":"G Argil\u00e9s","year":"2015","unstructured":"Argil\u00e9s G, Saunders MP, Rivera F, Sobrero A, Benson A, Guill\u00e9n Ponce C, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur J Cancer Oxf Engl 1990. 2015;51(8):942\u20139.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"6","key":"5753_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/annonc\/mdt056","volume":"24","author":"B Schultheis","year":"2013","unstructured":"Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, K\u00f6hne CH, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1560\u20137.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO."},{"issue":"6","key":"5753_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000382067","volume":"38","author":"R-D Hofheinz","year":"2015","unstructured":"Hofheinz R-D, Arnold D, Kubicka S, Prasnikar N, Vogel A. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat. 2015;38(6):300\u20138.","journal-title":"Oncol Res Treat"},{"key":"5753_CR25","unstructured":"Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (RE-ARRANGE) [Internet]. [cited 2017 Apr 25]. Available from: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02835924?term=regorafenib+120+colorectal&rank=8\n                    \n                  ."},{"issue":"6","key":"5753_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11523-017-0529-y","volume":"12","author":"A Gouverneur","year":"2017","unstructured":"Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-R\u00e9glat A, Pariente A, et al. Comparative safety of targeted therapies for metastatic colorectal Cancer between elderly and younger patients: a study using the international pharmacovigilance database. Target Oncol. 2017;12(6):805\u201314.","journal-title":"Target Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5753-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T23:51:30Z","timestamp":1591055490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5753"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5753-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Spanish Medicines Agency, by the Regional Clinical Research Ethics Committee of the Community of Madrid (reference number: Acta 5\/2013) and was performed in accordance with the Good Clinical Practice guidelines and the last version (Fortaleza 2013) of the Declaration of Helsinki. All patients provided written informed consent before enrolment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vi\u00e9itez has received honoraria for advisory activities from Bayer. Grande has received research fundings from Bayer, Astellas, Pfizer and AstraZeneca. Aranda has received honoraria for advisory role from Amgen, Bayer, Celgene, Merck, Roche and Sanofi. Carrato has received honoraria for advisory activities from Bayer, Pfizer, Merck and Shire. The other authors have stated that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"533"}}